Assessment of in vivo and in vitro genotoxicity of glibenclamide in eukaryotic cells

Glibenclamide is an oral hypoglycemic drug commonly prescribed for the treatment of type 2 diabetes mellitus, whose anti-tumor activity has been recently described in several human cancer cells. The mutagenic potential of such an antidiabetic drug and its recombinogenic activity in eukaryotic cells...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2015-03, Vol.10 (3), p.e0120675
Hauptverfasser:	de Sant'Anna, Juliane Rocha, Franco, Claudinéia Conationi da Silva, Mathias, Paulo Cezar de Freitas, de Castro-Prado, Marialba Avezum Alves
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Analysis Angina pectoris Anticancer properties Antitumor agents Aspergillus nidulans Cancer Cancer therapies Cell Proliferation - drug effects Cells (Biology) Cells, Cultured Chemicals Chemotherapy Cytokinesis Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - drug therapy Diabetes therapy Genotoxicity Glibenclamide Glyburide Glyburide - toxicity Heterozygosity Humans Hypoglycemic Agents - toxicity In vitro methods and tests In vivo methods and tests Kinetics Loss of heterozygosity Lymphocytes Lymphocytes - cytology Lymphocytes - drug effects Lymphocytes - metabolism Micronuclei Micronucleus Tests Mutagens - toxicity Mutation Potassium Recombination Rodents Studies Toxicology Type 2 diabetes Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!